Regeneron Pharmaceuticals, Inc. Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $15.5B+9.4% YoYTTM through 30 Jun 2026
Net Income $4.3B-1.9% YoYTTM through 30 Jun 2026
Free Cash Flow $3.8BTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 81.9% |
| EBITDA Margin | 28.1% |
| Operating Margin | 24.9% |
| Net Margin | 27.9% |
Returns
14.4%ROE
11.1%ROA
13.6%ROIC
Balance Sheet Health
Debt / Equity0.06x
Current Ratio4.13x
Net Debt-$6.6Bnet cash position
Cash & Equivalents$2.5B
Quality Metrics
Altman Z-Score7.27
Piotroski F-Score6 / 9
FCF Margin24.2%
Rule of 4033.2
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $14.3B
Diluted EPS$40.41TTMFY2025: $41.48
Dividend
$1.88Per share, FY20260.23%Yield
Capital Allocation
R&D Spend$6.3B
Capex Intensity5.9%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| EYLEA Franchise (U.S. Net Product Sales) | $4.4B | ||
| Sanofi Collaboration Revenue | $5.2B | +33.6% | View detailsExpect a step-up in Sanofi collaboration revenue starting in the third quarter of 2026 following the full repayment of the development balance by mid-year. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.